Kit for detecting rs2236410 polymorphism of MR1 gene and application thereof

By providing compositions and kits for detecting the polymorphism of MR1 gene rs2236410, the problem of graft-versus-host disease prediction and diagnosis after allogeneic hematopoietic stem cell transplantation is solved, rapid and accurate genotype detection is achieved, and the efficacy of transplantation is improved .

CN119061129APending Publication Date: 2024-12-03PEOPLES HOSPITAL PEKING UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310621865.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-30
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art is difficult to quickly and accurately detect the polymorphism of the MR1 gene rs2236410, which affects the prediction and diagnosis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Method used

Provides compositions for detecting the polymorphism of the MR1 gene, including specific primers and probes, to quickly and accurately detect genotypes in samples by real-time quantitative PCR technology, combining kits and nucleic acid extraction reagents for prediction and Diagnosed graft-versus-host disease.

Benefits of technology

The rapid and accurate detection of the polymorphism of the MR1 gene rs2236410 is achieved, and new prediction and diagnostic indicators are provided to help improve transplant efficacy and reduce the incidence of graft-versus-host disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004255617920000071
    Figure BDA0004255617920000071
  • Figure BDA0004255617920000111
    Figure BDA0004255617920000111
  • Figure BDA0004255617920000121
    Figure BDA0004255617920000121
Patent Text Reader

Abstract

The invention discloses a kit for detecting rs2236410 polymorphism of an MR1 gene and application of the kit. In particular discloses a composition for detecting the polymorphism of the MR1 gene rs2236410, and the composition comprises a primer rs2236410-F (SEQ ID No. 1), a primer rs2236410-R (SEQ ID No. 2), a probe rs2236410G (SEQ ID No. 3) and a probe rs2236410A (SEQ ID No. 4). The invention further discloses a kit for detecting the rs2236410 polymorphism of the MR1 gene and a detection method of the rs2236410 polymorphism of the MR1 gene. According to the kit and the detection method disclosed by the invention, the genotype of the MR1SNP rs2236410 site of a population can be rapidly and accurately detected, and a novel and reliable classification detection method for the genotype of the site is provided for conventional and batch detection in a clinical laboratory.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of molecular diagnosis, and in particular relates to a kit for detecting rs2236410 polymorphism of MR1 gene and application thereof. Background Art

[0002] Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective and even the only method for treating hematological malignancies. However, graft-versus-host disease (GVHD) is the main cause of morbidity and mortality after allo-HSCT, threatening the survival of patients after allo-HSCT. Among all patients receiving allo-HSCT, the incidence of grade I to IV acute GVHD (aGVHD) is 30%-50%, and the incidence of grade III to IV severe aGVHD is 14%. Early warning of the occurrence of acute GVHD after transplantation and timely targeted intervention are key factors in improving the efficacy of acute GVHD.

[0003] MHC class I-related protein 1 (MR1) is an MHC-I-like gene located on chromosome 1 and consists of 6 exons and 2 untranslated regions. Exon 1 encodes the leader peptide, and exons 2-4 encode the extracellular domain, including the α1 and α2 domains that form the antigen-binding cleft. Compared with the classical MHC-I gene, the MR1 molecule is highly conserved and can present vitamin B-related metabolites / ligands (riboflavin metabolite 5-OP-RU) from specific microbial sources to mucosa-associated invariant T (MAIT) cells. MAIT cells are enriched in mucosal tissues such as the human intestine and liver and in peripheral blood, and their T cell receptors (TCRs) express evolutionarily conserved constant α chains (human Vα7.2-Jα33) and β chains with limited Vβ variation (human Vβ2 or Vβ13). This high degree of conservation of MR1 and MAIT TCRα suggests that the MR1-dependent activation mode plays a key role in the development and immune regulation of MAIT cells.

[0004] Finding and identifying effective markers for diagnosing or predicting GVHD is one of the urgent problems to be solved in the clinic. Further development of rapid batch detection kits that can be used in clinical practice can provide the possibility of clinical transformation for predicting GVHD, which is conducive to further improving the efficacy of transplantation. Summary of the invention

[0005] The technical problem to be solved by the present invention is how to predict graft-versus-host disease after allogeneic hematopoietic stem cell transplantation and / or how to quickly and accurately detect the rs2236410 polymorphism of the MR1 gene. The technical problem to be solved is not limited to the described technical subject matter, and those skilled in the art can clearly understand other technical subjects not mentioned in this article through the following description.

[0006] To solve the above technical problems, the present invention first provides a composition for detecting the rs2236410 polymorphism of the MR1 gene, wherein the composition may include primer rs2236410-F, primer rs2236410-R, probe rs2236410G and probe rs2236410A, the nucleotide sequences of the primer rs2236410-F and the primer rs2236410-R may be shown as SEQ ID No.1 and SEQ ID No.2, respectively, and the nucleotide sequences of the probe rs2236410G and the probe rs2236410A may be shown as SEQ ID No.3 and SEQ ID No.4, respectively.

[0007] The nucleotide sequence of the MR1 gene is positions 181033387-181061938 of GenBank Accession No. NC_000001 (Update Date 20-MAR-2023).

[0008] The MR1 gene target sequence detected (targeted) by the primer rs2236410-F, the primer rs2236410-R, the probe rs2236410G and the probe rs2236410A may be: 5'-AAGGATCTGGATCATCTGGGACCCTACATGTCTTCCTTCTTTGCCTCCTTTCCAGGGACGCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCC[A / G]TGGGGTCCCTGAATTTATTTCGGTTGGGTACGTGGACTCGCACCCTATCACCACATATGACAGTGTCACTCGGCAGAAGGAGCCACGGGCCCCATGGATGGCAGAG-3' (SEQ ID No. 5).

[0009] The primer rs2236410-F and the primer rs2236410-R are used to specifically amplify the MR1 gene fragment containing the rs2236410 polymorphic site (A>G) of the MR1 gene, and the amplified nucleotide sequence of the MR1 gene fragment can be: 5'-GGTGATAGGGTGCGAGTCCACGTACCCAACCGAAATAAATTCAGGGACCCCA[C / T]GGATGGGATCCGAAACGCCCAGGCGAAAATATCTCAGAGAGTGCGTCCCTGG-3' (SEQ ID No.6).

[0010] The probe rs2236410G and the probe rs2236410A are used to detect the genotype of the rs2236410 polymorphic site of the MR1 gene.

[0011] The rs2236410 polymorphism (A>G) of the MR1 gene is a single nucleotide polymorphism (SNP), which is a mutation of the single nucleotide A (adenine) to G (guanine) at the rs2236410 polymorphic site of the MR1 gene. The alleles are A and G. The rs2236410 polymorphic site has three genotypes: A / A, A / G and G / G.

[0012] In the above composition, the probe rs2236410G and the probe rs2236410A can be labeled with different fluorescent groups.

[0013] The fluorescent group can be selected from at least one of FAM, VIC, HEX, TRT, CY3, CY5, ROX, JOE, FITC, TET, NED, TAMRA, LC RED640, LC RED705, Quasar705 or Texas Red. The fluorescent group can be labeled at the 3' end or the 5' end of the probe.

[0014] In the above composition, the 3' end of the probe rs2236410G can be labeled with FAM, and the 3' end of the probe rs2236410A can be labeled with VIC.

[0015] The present invention also provides a kit for detecting the rs2236410 polymorphism of the MR1 gene, and the kit may comprise any of the compositions described herein.

[0016] Furthermore, the kit may also include Taq DNA polymerase, dNTP, PCR buffer, Mg 2+ One or more of .

[0017] Furthermore, the kit may include Master Mix (TaqMan TM Gene Expression Mastermix, product of Applied Biosystems, catalog number 4369016).

[0018] Furthermore, the kit may also include a nucleic acid extraction reagent, which is used to extract nucleic acid from a biological sample (test sample) from a subject.

[0019] The various reagent components of the kit may be present in separate containers, or may be pre-combined in whole or in part into a reagent mixture.

[0020] Further, the kit may also include a readable carrier recording the method for detecting rs2236410 polymorphism of MR1 gene described herein. The readable carrier may be a kit instruction sheet (e.g., a printed instruction sheet) for practicing the method of the present invention or a computer-readable medium (e.g., a floppy disk, a CD, etc.) on which information has been recorded.

[0021] The test sample of the kit can be a blood sample (such as whole blood, plasma, serum or blood spot), a tissue sample, etc., but is not limited thereto.

[0022] The kit can be a MR1 gene polymorphism detection kit for predicting graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

[0023] The present invention also provides any of the following uses of any of the compositions described herein:

[0024] A1) Use in detecting rs2236410 polymorphism of MR1 gene or preparing a product for detecting rs2236410 polymorphism of MR1 gene;

[0025] A2) Use in the diagnosis or auxiliary diagnosis of graft-versus-host disease or in the preparation of a product for the diagnosis or auxiliary diagnosis of graft-versus-host disease;

[0026] A3) Use in the prediction of graft-versus-host disease or in the preparation of a product for the prediction of graft-versus-host disease.

[0027] The application described in A2) or A3) includes detecting the genotype of the rs2236410 polymorphism of the MR1 gene of the donor and the patient, and the incidence of severe and intestinal aGVHD and chronic GVHD is higher in patients with donor genotype A / A.

[0028] When the donor genotype is A / A, it is more likely to cause GVHD (especially intestinal aGVHD) in patients.

[0029] The donor and the patient may be a donor of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and a patient receiving allo-HSCT.

[0030] The present invention also provides the use of a substance for detecting the rs2236410 polymorphism of the MR1 gene in preparing a product for predicting, diagnosing or assisting in diagnosing graft-versus-host disease.

[0031] The substance for detecting the rs2236410 polymorphism of the MR1 gene may be any composition described in the present invention.

[0032] The present invention also provides the use of the rs2236410 polymorphic site of the MR1 gene as a prediction, diagnosis or auxiliary diagnosis marker for resistance to graft-versus-host disease.

[0033] The present invention also provides the application of the rs2236410 polymorphic site of the MR1 gene as a therapeutic target for resisting graft-versus-host disease.

[0034] The present invention also provides a method for detecting the rs2236410 polymorphism of the MR1 gene, which may include the following steps:

[0035] B1) extracting genomic DNA of the sample to be tested;

[0036] B2) using the genomic DNA as a template, performing real-time quantitative PCR (RQ-PCR) using any of the compositions described herein, and collecting fluorescent signals;

[0037] B3) Determining the genotype of the sample to be tested according to the fluorescence signal.

[0038] In the above method, the final concentrations of primer rs2236410-F and primer rs2236410-R in the composition are both 0.9 μmol / L.

[0039] In the above method, determining the genotype of the sample to be tested according to the fluorescent signal includes: continuously monitoring the intensity of the fluorescence emitted by the free fluorescent group in the reaction solution during the RQ-PCR reaction; determining the genotype of the sample to be tested according to the intensity change curve of the fluorescence of different colors emitted by the fluorescent groups of different colors during the RQ-PCR reaction.

[0040] Specifically, if the labeled fluorescent group only emits the intensity change curve of the FAM fluorescent group during the RQ-PCR reaction, the rs2236410 polymorphic site of the MR1 gene is a homozygous G / G genotype;

[0041] If the labeled fluorescent group emits the intensity change curve of both VIC and FAM fluorescent groups during the RQ-PCR reaction, the rs2236410 polymorphic site of the MR1 gene is a heterozygous A / G genotype;

[0042] If the labeled fluorescent group only emits the intensity change curve of the VIC fluorescent group during the RQ-PCR reaction, the rs2236410 polymorphic site of the MR1 gene is a homozygous A / A genotype.

[0043] In the above method, the reaction system of the RQ-PCR reaction may include: template DNA (test sample DNA), forward primer rs2236410-F, reverse primer rs2236410-R, probe rs2236410G, probe rs2236410A, Master Mix (TaqMan TM Gene Expression Master mix, product of Applied Biosystems, product number 4369016), deionized water.

[0044] Furthermore, the reaction system (20 μL) can be: template DNA 1 μL, forward primer rs2236410-F (100 μmol / L) 0.18 μL, reverse primer rs2236410-R (100 μmol / L) 0.18 μL, probe rs2236410G (100 μmol / L) 0.05 μL, probe rs2236410A (100 μmol / L) 0.05 μL, Master Mix 10 μL, and deionized water 8.54 μL.

[0045] In the above method, the reaction conditions of the RQ-PCR reaction may be: 50° C. for 2 minutes, 95° C. for 10 minutes, 95° C. for 15 seconds, 60° C. for 1 minute, and 45 cycles.

[0046] The sample to be tested described herein may be a blood sample (such as whole blood, plasma, serum or blood spot), a tissue sample, etc. but is not limited thereto.

[0047] The sample to be tested described in this article can be derived from a donor of allogeneic hematopoieticstem cell transplantation (allo-HSCT) or a patient who has received allo-HSCT.

[0048] The product described herein may be a reagent, a kit, a chip or a test paper.

[0049] The product described herein may include any of the compositions described herein for detecting the rs2236410 polymorphism of the MR1 gene.

[0050] The graft-versus-host disease (GVHD) described herein may include acute graft-versus-host disease (aGvHD).

[0051] The purposes of the above-mentioned applications and methods may be disease diagnosis, disease prognosis and / or disease treatment, and their purposes may also be non-disease diagnosis, non-disease prognosis and non-disease treatment purposes; their direct purpose may be to obtain information on intermediate results of disease diagnosis results, disease prognosis results and / or disease treatment results, and their direct purpose may be non-disease diagnosis, non-disease prognosis and / or non-disease treatment purposes.

[0052] The method for detecting rs2236410 polymorphism of MR1 gene provided by the present invention can be a non-disease diagnosis and treatment method or a disease diagnosis and treatment method. Among them, the non-disease diagnosis and treatment method can be, for example, detecting rs2236410 polymorphism of MR1 gene when screening or predicting diseases related to rs2236410 polymorphism of MR1 gene in a population, or performing susceptibility detection of diseases related to rs2236410 polymorphism of MR1 gene. The disease related to rs2236410 polymorphism of MR1 gene can be graft-versus-host disease (anti-graft-versus-host disease, GVHD).

[0053] In addition, the method of detecting rs2236410 polymorphism of MR1 gene in the present application can also have many other uses, such as gene polymorphism analysis and family evolution history research. The method of the present invention can also be used for sample research of non-specific objects, such as testing mixed blood products.

[0054] The MR1 gene is highly conserved, but previous studies have found that MR1 has multiple single nucleotide polymorphisms (SNPs). In patients with chronic myeloid leukemia (CML) receiving donor lymphocyte infusion (DLI) treatment, MR1 H17R rs2236410 (A>G) was identified as an HLA-II class-restricted minor histocompatibility antigen (mHag). MR1 H17R (rs2236410) is located just in the α1 domain of ligand binding, suggesting that H17R may be related to TCR recognition of MR1 ligands. This present invention verifies for the first time that donor MR1 rs2236410 participates in antigen presentation and mediates MAIT cell activation, thereby affecting the anti-GVHD effect of MAIT cells, especially severe aGVHD or intestinal aGVHD. Therefore, in the context of transplantation, MR1 rs2236410 can be used as a new biological marker to predict the occurrence of GVHD, and it can also be a potential target for anti-GVHD. Currently, there is no simple kit that can be used for batch detection of MR1 rs2236410 polymorphism in clinical laboratories. Therefore, there is an urgent need for a kit that can be used for rapid batch detection of MR1rs2236410 in clinical practice, which can provide the possibility of clinical transformation for the prediction of aGVHD based on MR1 rs2236410 polymorphism and ultimately further improve the efficacy of transplantation.

[0055] The invention discloses a gene polymorphism (MR1 rs2236410) detection kit for predicting graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. The kit comprises a forward primer (primer rs2236410-F), a reverse primer (primer rs2236410-R), a fluorescently labeled wild-type probe (probe rs2236410A) and a mutant probe (probe rs2236410G), and the kit can quickly and accurately detect the genotype of the MR1 rs2236410 site of a donor or a transplant patient. The kit for detecting the MR1 gene rs2236410 polymorphism of the invention and the detection method thereof can quickly and accurately detect the genotype of the MR1 SNP rs2236410 site of a population, quickly and accurately classify the MR1 genotype of a hematopoietic stem cell transplantation donor patient, and further be used for predicting, diagnosing or auxiliary diagnosis of graft-versus-host disease (GVHD), providing a new and reliable genotype classification detection method for the site for routine and batch detection in clinical laboratories. The MR1 SNP rs2236410 genotype (wild type or mutant type) detected by the kit of the present invention can be used as one of the GVHD prediction indicators of allo-HSCT, and has important guiding significance for the prognosis of hematopoietic stem cell transplantation patients and the formulation of clinical treatment plans for graft-versus-host disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0056] Figure 1The RQ-PCR instrument software plotted the allele identification data results as a MR1 rs2236410 genotype dot plot ( Figure 1 A) and MR1 gene SNP rs2236410 site diagram ( Figure 1 (B).

[0057] Figure 2 To investigate the effect of donor rs2236410 locus genotype on GVHD after transplantation.

[0058] Figure 3 The percentage of MAIT cells (%CD3 + Comparison of the number of T cells) [BM: n(A / A) = 57, n(A / G) = 56; PB: n(A / A) = 83, n(A / G) = 81].

[0059] Figure 4 In vitro experiments confirmed the response ability of MAIT cells from donors of different genotypes to Escherichia coli (vitamin B-related metabolites / ligands derived from bacterial flora). Figure 4 A is MAIT cells (CD3 + CD161 + Vα7.2 + ) flow cytometry gating strategy; Figure 4 Middle B shows the fold change of MR1 expression ratio on lymphocytes of donors with different genotypes after co-culture with E. coli for 20 h compared with the PBS group [(n(A / A)=9, n(A / G)=8)].

[0060] Figure 5 Comparison of the expression of functional factors of MAIT cells from donors with different genotypes stimulated by E. coli in vitro; [n(A / A)=9, n(A / G)=8]. Figure 5 Middle A is the fold change of the proportion of MAIT cells from donors of different genotypes after 20 h of co-culture with E. coli compared with the PBS group [n(A / A)=9, n(A / G)=8]; Figure 5 Medium B and Figure 5 Middle C shows the fold changes of activation marker CD69 and transcription factors of MAIT cells from donors with different genotypes compared with the PBS group after 20 h of co-culture with E. coli [n(A / A)=9, n(A / G)=8]; Figure 5 D in the middle shows the fold changes of functional cytokines in MAIT cells from donors of different genotypes compared with the PBS group after co-culture with E. coli for 20 h [n(A / A)=9, n(A / G)=8]. DETAILED DESCRIPTION

[0061] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.

[0062] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.

[0063] The nucleotide sequence of the MR1 gene in the following examples is 181033387-181061938 of GenBank Accession No. NC_000001 (Update Date 20-MAR-2023).

[0064] Example 1: Design of primers and probes for detecting rs2236410 polymorphism of MR1 gene

[0065] The inventors conducted a lot of research, analysis and comparison, and first determined that the target sequence for detecting the rs2236410 polymorphism of the MR1 gene is: 5'-AAGGATCTGGATCATCTGGGACCCTACATGTCTTCCTTCTTTGCCTCCTTTCCAGGGACGCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCC[A / G]TGGGGTCCCTGAATTTATTTCGGTTGGGTACGTGGACTCGCACCCTATCACCACATATGACAGTGTCACTCGGCAGAAGGAGCCACGGGCCCCATGGATGGCAGAG-3' (SEQ ID No.5). Then two primers and two probes (covering the wild-type and mutant sequences, respectively) were designed for the target sequence, and the two probes were labeled with different fluorescent groups to detect different alleles. The primer and probe sequences are shown in Table 1:

[0066] Table 1. Primer and probe sequences

[0067]

[0068] The designed primers (forward primer rs2236410-F and reverse primer rs2236410-R) were used to specifically amplify the MR1 gene fragment containing the rs2236410 polymorphic site (A>G) of the MR1 gene. The amplified nucleotide sequence of the MR1 gene fragment is as follows: 5'-GGTGATAGGGTGCGAGTCCACGTACCCAACCGAAATAAATTCAGGGACCCCA[C / T]GGATGGGATCCGAAACGCCCAGGCGAAAATATCTCAGAGAGTGCGTCCCTGG-3' (SEQ ID No.6).

[0069] The designed probe was used to detect the genotype of the rs2236410 polymorphism site of the MR1 gene.

[0070] The rs2236410 polymorphism (A>G) of the MR1 gene is a single nucleotide polymorphism (SNP), which is a mutation of the single nucleotide A (adenine) to G (guanine) at the rs2236410 polymorphic site of the MR1 gene. The alleles are A and G. The rs2236410 polymorphic site has three genotypes: A / A, A / G and G / G.

[0071] Example 2: Establishment of a kit and a detection method for detecting rs2236410 polymorphism of the MR1 gene

[0072] Real-time quantitative (RQ)-PCR was used to analyze the MR1 rs2236410 genotype of the subjects' bone marrow / peripheral blood and other specimens DNA, and a kit and detection method were created that can quickly and accurately detect the genotype of this SNP site.

[0073] The kit for detecting the rs2236410 polymorphism of the MR1 gene is configured with a forward primer rs2236410-F (SEQ ID No. 1), a reverse primer rs2236410-R (SEQ ID No. 2), a probe rs2236410G (SEQ ID No. 3) and a probe rs2236410A (SEQ ID No. 4).

[0074] The method for detecting the rs2236410 polymorphism of the MR1 gene is as follows:

[0075] 1. Extract genomic DNA from the sample to be tested

[0076] 1.1. Sample collection: The sample to be tested is whole blood or bone marrow, and the cell volume of the sample is 1×106 ~2×10 6 .

[0077] 1.2 DNA extraction

[0078] (1) Lysis of red blood cells: Prepare 50 mL centrifuge tubes with 20 mL of red blood cell lysis buffer and add 8-10 mL of anticoagulated whole blood or 1-2 mL of bone marrow to each tube. Mix the specimens, record the corresponding specimen number on the centrifuge tubes, and incubate the centrifuge tubes on a shaker at room temperature for 5 minutes to lyse the red blood cells.

[0079] (2) Centrifuge at 2000 rpm for 5 minutes, discard the supernatant, and adjust the cell volume. Add an appropriate amount of physiological saline according to the number of white blood cells at the bottom of the tube after centrifugation, and gently pipette to resuspend and wash the cells.

[0080] (3) Centrifuge at 2000 rpm for 5 minutes and discard the supernatant. Then add 600 μL of DNAzol to each tube and mix with a pipette until there is no resistance and it is not sticky.

[0081] (4) After standing at room temperature for 15 minutes, add 600 μL of anhydrous ethanol, mix thoroughly by inversion, and leave at room temperature for 1-3 minutes. A white flocculent precipitate of DNA can be seen.

[0082] (5) Add 600 μL of 80% ethanol to rinse the DNA once. During the rinse, suspend the DNA in ethanol, invert the centrifuge tube 3-6 times, and then use the tip of a gun to suck away the excess liquid, leaving the white DNA. Leave it at room temperature for about 10 minutes to evaporate the excess alcohol.

[0083] (6) Add appropriate amount of water to dissolve the DNA.

[0084] 1.3 DNA concentration determination and dilution

[0085] The DNA concentration was determined and diluted to 1-20 ng / μL for subsequent SNP detection.

[0086] 2. RQ-PCR (real-time quantitative PCR) detection

[0087] Using the genomic DNA extracted in step 1 as a template, RQ-PCR reaction was performed using the forward primer rs2236410-F (SEQ ID No. 1), the reverse primer rs2236410-R (SEQ ID No. 2), the probe rs2236410G (SEQ ID No. 3) and the probe rs2236410A (SEQ ID No. 4) designed in Example 1.

[0088] The reaction system of RQ-PCR reaction includes: template DNA (sample DNA to be tested), forward primer rs2236410-F, reverse primer rs2236410-R, probe rs2236410G, probe rs2236410A, Master Mix (TaqMan TM GeneExpression Master mix, Applied Biosystems product, catalog number 4369016), deionized water. The volume of Master Mix accounts for 1 / 3-1 / 2 of the total reaction system; the stock concentrations of primers and probes are both 100 μmol / L, the final working concentration of diluted primers is 0.9 μmol / L, and the working concentration of diluted probes is 0.2-0.5 μmol / L.

[0089] Specifically, the reaction system (20 μL) of the RQ-PCR reaction was: 1 μL of template DNA, 0.18 μL of forward primer rs2236410-F (100 μmol / L), 0.18 μL of reverse primer rs2236410-R (100 μmol / L), 0.05 μL of probe rs2236410G (100 μmol / L), 0.05 μL of probe rs2236410A (100 μmol / L), 10 μL of Master Mix, and 8.54 μL of deionized water.

[0090] The reaction conditions of the RQ-PCR reaction were: 50°C for 2 min, 95°C for 10 min, 95°C for 15 s, 60°C for 1 min, and 45 cycles.

[0091] 3. Result determination

[0092] During the RQ-PCR reaction, the intensity of the fluorescence emitted by the free fluorescent groups in the reaction solution is continuously monitored; the genotype of the sample to be tested is determined based on the intensity change curve of the fluorescence of different colors emitted by the fluorescent groups of different colors during the RQ-PCR reaction.

[0093] Specifically, if the labeled fluorescent group only emits the intensity change curve of the FAM fluorescent group during the RQ-PCR reaction, the rs2236410 polymorphic site of the MR1 gene is a homozygous G / G genotype;

[0094] If the labeled fluorescent group emits the intensity change curve of both VIC and FAM fluorescent groups during the RQ-PCR reaction, the rs2236410 polymorphic site of the MR1 gene is a heterozygous A / G genotype;

[0095] If the labeled fluorescent group only emits the intensity change curve of the VIC fluorescent group during the RQ-PCR reaction, the rs2236410 polymorphic site of the MR1 gene is a homozygous A / A genotype.

[0096] Example 3: Clinical verification of the accuracy of the MR1 gene rs2236410 polymorphism detection method

[0097] This example verifies the clinical significance of the MR1 rs2236410 genotype detected by the kit of the present invention in clinical cohorts and in vitro experiments, and the method is as follows:

[0098] 1. Cell surface monoclonal antibody labeling

[0099] (1) Mix the whole blood and count the white blood cells;

[0100] (2) Add 100-200 μL whole blood (white blood cell count ≤ 1×10 6 ) to the flow tube;

[0101] (3) Add the corresponding cell surface flow cytometry antibodies (CD3-Percp, CD69-BV510, CD161-PE-cy7 / BV510, Vα7.2-PE / APC, HLA-DR-BB515, T-bet-AF488, RORγt-PE-CF594, IL-17-BV421, TNF-α-BV605, IFN-γ-APC, Perforin-BV711, Granzyme B-AF-647, all of which are from BD Company, and the dosage is determined according to the instructions of each antibody product), and incubate at room temperature in the dark for 20 min;

[0102] (4) Add 2 mL of 1× BD Lysing solution (BD product, catalog number 349202, stock solution is 10×, needs to be diluted 10 times with distilled water, PBS dilution is prohibited) and let stand at room temperature for 8 min;

[0103] (5) Centrifuge at 400 g for 5 min and discard the supernatant;

[0104] (6) Add 2 mL of PBS to resuspend, centrifuge at 400 g for 5 min, remove the supernatant, and prepare for the instrument (Cytek NL 3000 full spectrum flow cytometer);

[0105] (7) If there are any visible particles before loading, they must be filtered out by a filter.

[0106] 2. Intracellular antigen labeling

[0107] (1) Surface marking is first performed, and the specific operations are as follows (1) to (6) in step 1 of this embodiment;

[0108] (2) Resuspend the cells by flicking, add 1 mL of the prepared eBioscience Transcription Factor Buffer Set (BD Bioscience, USA, Catalog No. 562574) (fixation / permeabilization diluent = 1:3), and vortex for 30 seconds;

[0109] (3) Incubate at 4°C in the dark for 30 min;

[0110] (4) Directly add 2 mL of 1× permeablization buffer and centrifuge at 600 g for 5 min;

[0111] (5) Discard the supernatant, resuspend by flicking, add the corresponding intracellular antibody, and incubate at room temperature for 20 min;

[0112] (6) Add 2 mL of 1× permeabilization buffer and centrifuge at 600 g for 5 min.

[0113] (7) Discard the supernatant, add 100 μL 1× permeabilization buffer to resuspend, and load onto the microarray;

[0114] (8) If there are any visible particles before loading, they must be filtered out by a filter.

[0115] 3. On-machine testing

[0116] a) Determine the optimal voltage and compensation: Set the voltage according to the routine operating procedures of the Cytek NL 3000 full-spectrum flow cytometer, and prepare single-stained samples according to the fluorescent color matching of this kit for instrument setting.

[0117] b) Instrument setup, calibration and quality control: Turn on the machine and preheat it for more than 20 minutes and rinse it with deionized water. Test the internal quality control products to ensure that all test values ​​are within the control range. Load the AL PANAL sample and collect data.

[0118] c) On-machine testing: According to the set instrument conditions, obtain 50,000-100,000 cells per tube. If the test cannot be carried out on the machine in time, add 0.5 mL of 1% paraformaldehyde, mix well and store in a 4°C refrigerator. Complete the test within 24 hours. + CD161 + Vα7.2 + MAIT cells are defined as cells expressing CD3 + CD161 - Vα7.2+ The cells with MAIT expression were defined as non-MAIT cells.

[0119] 4. Analyze data using FlowJo software

[0120] 5. In vitro Escherichia coli stimulation experiment

[0121] 5.1. Immobilization of Escherichia coli

[0122] a) Escherichia coli (DH5α) was cultured in lysate broth (LB) medium at 37°C for 16 h;

[0123] b) Measure the number of colony forming units (CFU) of bacteria and adjust the concentration to the equivalent of 5×10 11 CFU / mL;

[0124] c) The cells were then fixed in 2% paraformaldehyde (PFA) for 20 min, followed by PBS washing, and the fixed E. coli were stored at 4°C.

[0125] 5.2 In vitro stimulation

[0126] a) Peripheral mononuclear cells (PBMCs) isolated from each healthy donor were placed in a two-well flat-bottom plate with 1×10 6 cells;

[0127] b) One of the holes is 1×10 6 The E. coli with fixed CFU was stimulated and co-cultured at 37°C, 5% CO2 for 20 h; an equal amount of PBS was added to the other well and cultured at 37°C, 5% CO2 for 20 h.

[0128] c) Finally, the cells from the two wells were collected and stained with antibodies according to the intracellular staining protocol for flow cytometry detection.

[0129] The above method was used to study 189 patients and their donors who received allo-HSCT for the first time at Peking University People's Hospital from March 1, 2019 to November 1, 2019 and from July 1, 2021 to September 1, 2021. Secondary transplantation cases were excluded from the included patients, and healthy donors were required to complete pre-transplantation examinations and meet the requirements as allo-HSCT donors. Case selection and sample collection were approved by the Ethics Committee of Peking University People's Hospital (Ethics No. 2018PHB222-01) and were performed with the consent of the patients or legal guardians.

[0130] All patients were given granulocyte colony-stimulating factor (G-CSF, 5 μg / kg / d, for 5 consecutive days) to mobilize bone marrow (G-BM) and peripheral blood (G-PB) before transplantation. The mononuclear cell count (MNC) was greater than 6×10 8 / kg. On the day of transplantation, unprocessed bone marrow (collected on day 4 after G-CSF) and peripheral blood stem cells (PBSCs, collected on day 5 after G-CSF) were infused into the recipient. All patients received either G-BM and G-PB allogeneic transplantation simultaneously or G-PB alone. All patients in this study received myeloablative conditioning regimen.

[0131] A total of 189 transplant patients and their donors were enrolled in the clinical cohort of this study. The clinical characteristics of the patients and donors are shown in Table 2 .

[0132] Table 2 Clinical characteristics of donors and patients

[0133]

[0134]

[0135] * Genotype data were missing for 16 patients' pre-transplant samples.

[0136] Among the 189 transplanted patients, 83.6% (158 / 189) received haploid transplantation. The incidence of aGVHD was 39.2% (74 / 189), of which the incidence of stage II-IV aGVHD was 24.3% (46 / 189). During the follow-up period, the relapse rate was 8.5% (16 / 189) and the mortality rate was 7.4% (14 / 189).

[0137] The SNP genotyping analysis was performed on DNA samples of 189 registered donors and pre-transplant patients by the RQ-PCR detection method of the present invention (i.e., the detection method in Example 2). The allele discrimination diagram showed relatively accurate wild-type (A / A) and heterozygous mutant (A / G) genotypes ( Figure 1 In order to verify the accuracy of SNP genotyping analysis, we performed Sanger sequencing on samples with suspicious results. The results also further confirmed the genotype distribution of A / A and A / G, and no homozygous mutation (G / G) results were found ( Figure 1B). The Sanger sequencing results verified the accuracy of the kit and its detection method of the present invention and the presence of A>G substitution at the MR1rs2236410 locus. The frequencies of these two genotypes in donors and pre-transplant patients were further observed. The results showed that the frequencies of A / A genotype (47.6%) and A / G genotype (52.4%) in healthy donors were similar, while the frequency of A / G genotype (63.6%) in pre-transplant patients was significantly higher than that of A / A genotype (36.4%) (P<0.001) (Table 3).

[0138] Table 3. Correlation analysis between genotype and related clinical events

[0139]

[0140]

[0141] Under the myeloablative preconditioning transplantation system, patients with good engraftment will show complete donor genotype chimerism, so we divided the patients into two groups according to the donor genotype. The results showed that patients with donor genotype A / A had a higher incidence of severe and intestinal aGVHD and chronic GVHD, while patients with genotype A / G had a higher incidence of type I aGVHD ( Figure 2 ). In our cohort, the GVHD grading of intestinal aGVHD was basically grade II or above. These partial results suggest that donor genotype A / A may be one of the factors affecting severe GVHD, especially intestinal aGVHD. Univariate analysis also found that the incidence of intestinal (8.5% vs. 4.8%) and II-IV aGVHD (14.3% vs. 10.1%) was higher in donors with genotype A / A compared with genotype A / G (Table 3).

[0142] To determine the functional significance of MR1 rs2236410, we examined the proportion of MAIT cells in the PB (peripheral blood) and BM (bone marrow) of A / G mutant donors and compared them with wild-type A / A donors. We found that A / G donors had a higher proportion of MAIT cells in both BM and PB ( Figure 3 To verify whether the differences in the proportions of MAIT cells of different genotypes were due to the different abilities of antigen-presenting cells to present MAIT cell-activating ligands, PBMCs of donors of different genotypes were stimulated in vitro with Escherichia coli ( Figure 5 The results showed that after stimulation with E. coli, the MAIT cells from A / G donors had a higher fold change compared to those from A / A donors ( Figure 4 We examined the expression of MR1 in both genotypes before and after E. coli stimulation. Both genotypes induced upregulation of MR1 on lymphocytes, but the A / G genotype showed a greater fold increase in MR1 expression ( Figure 4Thus, these results suggest that MR1 rs2236410 has a direct effect on MR1-restricted antigen presentation.

[0143] Further analysis of MAIT cell activation after antigen presentation showed that the expression of CD69, an activation marker of MAIT cells, was upregulated more in the A / G genotype than in the A / A genotype after stimulation (P = 0.011). Figure 4 ). These results confirm that MR1 rs2236410 may affect the development and activation of MAIT cells by affecting specific antigen presentation.

[0144] T-bet and RORγt are important transcription factors for MAIT cells to exert different immune functions. The results showed that after stimulation with E. coli, the expression of these two transcription factors was upregulated in MAIT cells of both genotypes, especially in the A / G genotype ( Figure 5 In addition, compared with the A / A genotype, the expression of RORγt in MAIT cells of the A / G genotype was significantly upregulated ( Figure 5 In terms of the expression of cytotoxic factors (IFN-γ, TNF-α, granzyme B, and perforin), both genotypes were upregulated after stimulation, but the A / G genotype had a greater upregulation ( Figure 5 In D). Our previous work (published in Front Immunol. 2021 Sep 3; 12: 720354.) found that RORγt-positive MAIT cells are the main expression subpopulation of IL-17A and are associated with anti-intestinal aGVHD. The results of this study showed that after E. coli stimulation, IL-17A in MAIT cells of A / G donors was upregulated more than that in A / A donors ( Figure 5 These results suggest that MR1 rs2236410 is involved in the anti-GVHD effect by affecting the activation and function of MAIT cells.

[0145] It can be seen that the donor MR1 rs2236410 genotype can effectively predict the occurrence of GVHD in patients after transplantation, especially severe or intestinal GVHD. Compared with the mutant A / G, the incidence of severe or intestinal aGVHD in patients with donor A / A genotype is higher.

[0146] In summary, MR1 rs2236410 participates in antigen presentation and mediates the activation of MAIT cells, thereby affecting the anti-GVHD effect of MAIT cells. It can be used as a new biological marker for predicting GVHD in transplantation scenarios and as a potential target for anti-GVHD. The kit of the present invention can quickly and accurately determine the genotype of the donor MR1 rs2236410 locus, providing a new early warning marker for clinical intervention and treatment plan formulation of GVHD after hematopoietic stem cell transplantation.

[0147] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, and without the need to carry out unnecessary experimental conditions, the present invention can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present invention provides specific embodiments, it should be understood that the present invention can be further improved. In a word, according to the principles of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departure from the disclosed scope in the application, and changes made with conventional techniques known in the art.

Claims

1. A composition for detecting rs2236410 polymorphism of MR1 gene, characterized in that: The composition comprises primer rs2236410-F, primer rs2236410-R, probe rs2236410G and probe rs2236410A, the nucleotide sequences of primer rs2236410-F and primer rs2236410-R are shown as SEQ ID No.1 and SEQ ID No.2, respectively, and the nucleotide sequences of probe rs2236410G and probe rs2236410A are shown as SEQ ID No.3 and SEQ ID No.4, respectively.

2. The composition according to claim 1, characterized in that The probe rs2236410G and the probe rs2236410A are labeled with different fluorescent groups.

3. The composition according to claim 2, characterized in that The 3' end of the probe rs2236410G was labeled with FAM, and the 3' end of the probe rs2236410A was labeled with VIC.

4. A kit for detecting rs2236410 polymorphism of MR1 gene, characterized in that: The kit comprises the composition according to any one of claims 1 to 3.

5. Any of the following uses of the composition according to any one of claims 1 to 3: A1) Use in detecting rs2236410 polymorphism of MR1 gene or preparing a product for detecting rs2236410 polymorphism of MR1 gene; A2) Use in the diagnosis or auxiliary diagnosis of graft-versus-host disease or in the preparation of a product for the diagnosis or auxiliary diagnosis of graft-versus-host disease; A3) Use in the prediction of graft-versus-host disease or in the preparation of a product for the prediction of graft-versus-host disease.

6. Use of a substance for detecting the rs2236410 polymorphism of the MR1 gene in the preparation of a product for predicting, diagnosing or assisting in the diagnosis of graft-versus-host disease.

7. Application of the rs2236410 polymorphism of the MR1 gene as a predictive, diagnostic or auxiliary diagnostic marker for graft-versus-host disease.

8. Application of the rs2236410 polymorphism of the MR1 gene as a therapeutic target for anti-graft-versus-host disease.

9. A method for detecting rs2236410 polymorphism of MR1 gene, characterized in that: The method comprises the following steps: B1) extracting genomic DNA of the sample to be tested; B2) using the genomic DNA as a template, performing real-time quantitative PCR using the composition according to any one of claims 1 to 3, and collecting fluorescent signals; B3) Determining the genotype of the sample to be tested according to the fluorescent signal.

10. The method according to claim 9, characterized in that The final concentrations of the primer rs2236410-F and the primer rs2236410-R in the composition are both 0.9 μmol / L.